LEO Pharma Set for Five Late-Breaking Presentations at EADV
LEO Pharma A/S will present new clinical and real-world data from across its portfolio of products at the 33rd European Academy of Dermatology and Venereology (EADV) Congress from September 25-28 in Amsterdam, Netherlands, the company announced.
Five coveted late-breaking presentations will be given, in addition to 23 scientific posters for a range of skin conditions, forming the largest collection of data LEO Pharma has ever shared at the EADV congress, according to a press release.
“It is extraordinary to witness the breadth and variety of LEO Pharma’s scientific contribution at this year’s EADV Congress,” Christophe Bourdon, CEO of LEO Pharma, said. “It is a record-breaking presence for us—and we cannot wait to share this ground-breaking data with the medical dermatology community,.
The first late-breaking presentation for Anzupgo® (delgocitinib) cream will provide data from the 24-week DELTA FORCE trial that compared the efficacy and safety of topical delgocitinib cream with oral alitretinoin capsules in adults with severe CHE. An additional late-breaking oral presentation will provide data from the matching-adjusted indirect comparison (MAIC) of the efficacy of delgocitinib and dupilumab in the treatment of moderate to severe atopic hand eczema. The third delgocitinib cream late-breaking presentation will provide information on biomarker and efficacy data from the randomized vehicle-controlled clinical trial with delgocitinib cream in patients with frontal fibrosing alopecia.
A late-breaking presentation will also be presented for Adtralza/Adbry, highlighting the interim real-world effectiveness results of tralokinumab in adult patients with head and neck atopic dermatitis after up to 9 months of treatment in the TRACE real world evidence (RWE) study.
Finally, a late-breaking presentation for temtokibart will also be presented, comparing clinical and molecular responses in the targeting of IL-22RA1 with temtokibart vs dupilumab in patients with moderate to severe atopic dermatitis.
"The 2024 EADV Congress marks a pivotal moment for LEO Pharma as we unveil a wealth of new data," Kreesten Meldgaard Madsen, Chief Development Officer for LEO Pharma, said. "Our presentations at EADV showcase our most comprehensive research portfolio to date, underscoring our unwavering commitment to developing innovative dermatological therapies and helping to bring new hope to patients grappling with challenging skin conditions."